DYN supply chain intelligence for Dyne Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Dyne Therapeutics, Inc. (DYN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| VENDOR | VENDOR | 90% | Pursuant to an agreement with a vendor providing contract research and manufacturing services, the vendor has provided the Company with extended payment terms with respect to a portion of the service… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the ris… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ARWR gra… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from DYN graph: pagation, compounding, or processing at a separate establishment outside the United States prior to being imported … |
| CELG-RI | CELG-RI | 72% | pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. If we or any of our third-party manufa… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CPRX graph: Reciprocal relationship from DYN graph: Reciprocal relationship from CPRX graph: Reciprocal relationship from DYN graph: Reciprocal relationship from CPRX gra… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from HRMY gra… |
| MAZE | Maze Therapeutics, Inc. | 72% | Reciprocal relationship from MAZE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| MAZE | Maze Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| MRK | Merck & Co., Inc. | 72% | pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. If we or any of our third-party manufa… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph: pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or o… |
| RNA | Atrium Therapeutics, Inc. | 72% | Reciprocal relationship from RNA graph: logy, to address the root cause of genetic diseases of the heart. We are advancing our first two wholly-owned precision cardiology development candidates targe… |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from DYN graph: that the FORCE platform achieved delivery to the CNS. Intravenous, or IV, administration of FORCE conjugate, our propr… |
| RNAM | RNAM | 72% | that the FORCE platform achieved delivery to the CNS. Intravenous, or IV, administration of FORCE conjugate, our proprietary Fab antibody conjugated to an ASO, achieved delivery to the CNS via TfR1 i… |
| SRRK | Scholar Rock Holding Corporation | 72% | Reciprocal relationship from SRRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| SRRK | Scholar Rock Holding Corporation | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: Reciprocal relationship from DYN graph: Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and t… |
| TRDA | Entrada Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| WVE | Wave Life Sciences Ltd. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ALNY gra… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from DYN graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from DYN graph: pagation, compounding, or proce… |
| CELG-RI | CELG-RI | 72% | pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. If we or any of our third-party manufa… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| CPRX | Catalyst Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CPRX graph: Reciprocal relationship from DYN graph: Reciprocal relationship from CPRX graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| HTGC | Hercules Capital, Inc. | 72% | nced central nervous system delivery and potential use in neurological indications. In preclinical studies, both conjugates achieved robust MAPT RNA knockdown (approximately 75% for Conjugate 2) in b… |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from DYN graph: nced central nervous system delivery and potential use in neurological indications. In preclinical studies, both conju… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from DYN graph: Reciprocal relationship from IONS graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| MAZE | Maze Therapeutics, Inc. | 72% | Reciprocal relationship from MAZE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significan… |
| MAZE | Maze Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| MRK | Merck & Co., Inc. | 72% | pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. If we or any of our third-party manufa… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from MRK graph:… |
| RNAM | RNAM | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from DYN graph: Reciprocal relationship from RNAM graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| SRPT | Sarepta Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from DYN graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from DYN graph: ces and our business and operations, … |
| SRRK | Scholar Rock Holding Corporation | 72% | Reciprocal relationship from SRRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from SRRK gra… |
| SRRK | Scholar Rock Holding Corporation | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub… |
| TRDA | Entrada Therapeutics, Inc. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| WVE | Wave Life Sciences Ltd. | 72% | ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number of third-party suppliers and service pr… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant… |
| BIO | Bio-Rad Laboratories, Inc. | 62% | Reciprocal relationship from BIO graph: Reciprocal relationship from DYN graph: Reciprocal relationship from BIO graph: Reciprocal relationship from DYN graph: Reciprocal relationship from BIO graph:… |
| BMY | Bristol-Myers Squibb Company | 62% | Reciprocal relationship from BMY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from BMY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from BMY graph:… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DYN-DEBT | Debt stack $9.9M | 90% | Market cache reports total debt of $9.9M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DYN-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME | T. Rowe Price Investment Management, Inc. | 90% | 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 232 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALT | Altimmune, Inc. | 100.00 | 2 | |
| RGNX | REGENXBIO Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| HTGC | Hercules Capital, Inc. | 100.00 | 1 | ['customer'] |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| IRON | Disc Medicine, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| CVSI | CV Sciences, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| CAPR | Capricor Therapeutics, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 |